BriaCell Therapeutics Corp. (BCTX) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended January 31, 2026. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies for cancer. Key programs include Bria-IMT (targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer under FDA Fast Track Designation) and Bria-OTS (personalized off-the-shelf immunotherapy). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2026 | Six Months Ended Jan 31, 2026 | Balance Sheet (Jan 31, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss (Attributable to BriaCell) | $(7,221,820) | $(15,419,385) | N/A |
| Operating Expenses | $7,531,266 | $15,854,209 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $29,903,628 |
| Total Assets | N/A | N/A | $33,594,454 |
| Working Capital | N/A | N/A | $28,993,334 |
| Accumulated Deficit | N/A | N/A | $(127,174,949) |
| Net Cash Used in Operating Activities | N/A | $(15,672,094) | N/A |
Note: The company has no revenue. Margins are not applicable.
Material Changes vs. Prior Period
- Financing Activity: In January 2026, the company completed a public offering of units generating approximately $30.0 million in gross proceeds. This significantly increased cash balances from $10.5 million (July 31, 2025) to $29.9 million (January 31, 2026).
- Share Count: Outstanding common shares increased from 1,883,906 (July 31, 2025) to 7,250,487 (January 31, 2026) due to the public offering and warrant exercises.
- Operating Expenses: Research and development (R&D) expenses increased to $12.7 million for the six-month period (vs. $9.4 million in the prior year), driven by the advancement of the Bria-IMT Phase 3 trial and the Bria-OTS Phase 1/2a program.
- Warrant Liability: The fair value of warrant liabilities decreased from $337,672 to $195,096, resulting in a non-cash gain of $142,576 for the six-month period.
Outlook, Risks, and Management Commentary
- Clinical Progress: The pivotal Phase 3 study for Bria-IMT in metastatic breast cancer is on track for a topline data readout in the first half of 2026, with over 160 patients enrolled. Positive Phase 2 data showing extended survival (up to 47 months) and tumor regression was highlighted.
- Going Concern: Management states that the company's ability to continue as a going concern is dependent on its ability to raise additional capital. While the recent $30M offering improved liquidity, the company has an accumulated deficit of $127M and expects to sustain operating losses in the foreseeable future.
- Subsequent Event (BriaPro Transaction): On February 18, 2026, BriaCell entered an agreement to sell its exclusive license for Soluble CD80 (sCD80) to its subsidiary, BriaPro Therapeutics Corp. BriaPro will issue shares to BriaCell (increasing BriaCell's ownership in BriaPro to ~78%) and provide a $3M credit facility. The transaction was approved by disinterested shareholders on March 5, 2026.
- Non-Dilutive Funding: The company received a $2.0 million SBIR grant from the National Cancer Institute to support the Bria-PROS+ prostate cancer program.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $29.9M cash balance to determine the runway for the Phase 3 trial completion.
- Dilution Impact: Assess the impact of the 7.25M outstanding shares and 7.02M outstanding warrants on future equity value.
- Phase 3 Timeline: Confirm the specific date for the Phase 3 topline data readout expected in H1 2026.
- BriaPro Transaction Closing: Monitor the closing of the sCD80 asset transfer to BriaPro and the issuance of the $3M credit facility.
- Grant Utilization: Track the utilization of the $2.0M NCI SBIR grant and the potential for the additional $1.2M tranche.